CL2020003364A1 - Tratamiento antidiabético cardiovascular y renal seguro - Google Patents

Tratamiento antidiabético cardiovascular y renal seguro

Info

Publication number
CL2020003364A1
CL2020003364A1 CL2020003364A CL2020003364A CL2020003364A1 CL 2020003364 A1 CL2020003364 A1 CL 2020003364A1 CL 2020003364 A CL2020003364 A CL 2020003364A CL 2020003364 A CL2020003364 A CL 2020003364A CL 2020003364 A1 CL2020003364 A1 CL 2020003364A1
Authority
CL
Chile
Prior art keywords
renal
cardiovascular
safe
antidiabetic treatment
antidiabetic
Prior art date
Application number
CL2020003364A
Other languages
English (en)
Inventor
Eynatten Maximilian Von
Odd-Erik Johansen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2020003364A1 publication Critical patent/CL2020003364A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere al tratamiento antidiabético cardiovascular y renal seguro.
CL2020003364A 2018-07-17 2020-12-23 Tratamiento antidiabético cardiovascular y renal seguro CL2020003364A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18184034 2018-07-17
EP18187272 2018-08-03
EP18197472 2018-09-28
EP18202843 2018-10-26
EP19177388 2019-05-29

Publications (1)

Publication Number Publication Date
CL2020003364A1 true CL2020003364A1 (es) 2021-07-02

Family

ID=67262338

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003364A CL2020003364A1 (es) 2018-07-17 2020-12-23 Tratamiento antidiabético cardiovascular y renal seguro

Country Status (12)

Country Link
US (3) US20200022985A1 (es)
EP (1) EP3823625A1 (es)
JP (2) JP2021530508A (es)
KR (1) KR20210035227A (es)
CN (1) CN112437666A (es)
AU (2) AU2019306036B2 (es)
BR (1) BR112020026164A2 (es)
CA (1) CA3103735A1 (es)
CL (1) CL2020003364A1 (es)
MX (1) MX2021000554A (es)
PH (1) PH12021550101A1 (es)
WO (1) WO2020016230A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CA2580266A1 (en) 2004-10-08 2006-04-20 Novartis Ag Combination of organic compounds
AU2006265975B2 (en) 2005-07-01 2011-12-15 Merck Sharp & Dohme Corp. Process for synthesizing a CETP inhibitor
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP6224084B2 (ja) * 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP2016510795A (ja) * 2013-03-15 2016-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用
US9526728B2 (en) * 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN109310697A (zh) * 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Also Published As

Publication number Publication date
JP2021530508A (ja) 2021-11-11
CA3103735A1 (en) 2020-01-23
PH12021550101A1 (en) 2021-09-27
US20240398817A1 (en) 2024-12-05
MX2021000554A (es) 2021-03-29
AU2019306036A1 (en) 2020-12-17
KR20210035227A (ko) 2021-03-31
US20220160717A1 (en) 2022-05-26
AU2025217272A1 (en) 2025-08-28
JP2024124413A (ja) 2024-09-12
EP3823625A1 (en) 2021-05-26
AU2019306036B2 (en) 2025-05-15
BR112020026164A2 (pt) 2021-03-23
US20200022985A1 (en) 2020-01-23
WO2020016230A1 (en) 2020-01-23
CN112437666A (zh) 2021-03-02

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MX377710B (es) Anticuerpos monoclonales contra bcma.
BR112019004785A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
CL2020003414A1 (es) Tratamiento antidiabético cardiovascular seguro
CL2016002455A1 (es) Anticuerpos multiespecíficos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112019004783A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
EA201591665A1 (ru) Оральные составы деферазирокса
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
MX2020010657A (es) Derivados de oxadiazolina.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MX2017011194A (es) Anticuerpos, usos y métodos.
MX385788B (es) Método de tratamiento con tradipitant.
DK3242957T3 (da) Bakterieholdige sammensætninger og fremgangsmåder til anvendelse af samme til behandling og/eller forebyggelse af gastrointestinale, metaboliske og/eller andre sygdomme
BR112018002382A2 (pt) novos anticorpos anti-gvpi humano e usos dos mesmos
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA201700142A1 (ru) Полимерная композиция для слоя элемента слоя
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
MX374286B (es) Compuestos organolepticos novedosos.
EA201692569A1 (ru) Полимиксины с низкой степенью замещения и композиции, их содержащие
CL2019000572A1 (es) Compuesto de imida y uso del mismo.
MX374569B (es) Compuestos organolépticos novedosos.
MX380297B (es) Compuestos organolépticos novedosos.